CHENGDU KANGHUA BI revenue for the last year amounted to 1.58 B CNY, the most of which — 1.58 B CNY — came from its highest performing source at the moment, Non-immune Planning Vaccine. The greatest contribution to the revenue figure was made by China — last year it brought CHENGDU KANGHUA BI 1.58 B CNY, and the year before that — 1.45 B CNY.